

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

mRNA vaccines in children aged 5-11 years, pregnancy outcomes, changes in COVID-19 symptoms

Peer reviewed journals featured:

- Systematic reviews on:
 - mRNA vaccines in children aged 5 to 11 years [here](#) and associated editorial [here](#)
 - Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against Omicron and severe disease [here](#) and associated commentary [here](#)
 - Comparing preprints of COVID-19 clinical trials and corresponding journal articles [here](#)
- Randomised trials of:
 - Molnupiravir as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC) [here](#)
 - VV116 vs nirmatrelvir–ritonavir for COVID-19 oral treatment [here](#)
 - Antimicrobial audit and feedback in hospitalised COVID-19 patients [here](#) and [here](#)
- Observational studies on:
 - Pregnancy outcomes and vaccine effectiveness during Omicron outbreak [here](#)
 - SARS-CoV-2 variant-related abnormalities detected by prenatal MRI [here](#)
 - Australian general practices adaptation to COVID-19 [here](#)
 - COVID-19 vaccination in cancer patients treated with immunotherapy [here](#)
 - Global investments in pandemic preparedness and COVID-19 [here](#) and [here](#)
 - Maternal, foetal, & newborn outcomes in women with SARS-CoV-2 infection [here](#)
 - Bivalent mRNA booster dose effectiveness in immunocompetent US adults [here](#)
 - COVID-19 as the underlying cause of death in children and young people in the US [here](#)
 - Natural course of health and well-being in non-hospitalised children and young people after testing for SARS-CoV-2 [here](#) and [here](#)
 - Omicron reinfection risk factors in previously infected frontline workers in the US [here](#)
 - SARS-CoV-2 incubation period during the Omicron BA.5–dominant period in Japan [here](#)

Commentary on:

- How COVID-19 symptoms are changing [here](#)
- Facing the new COVID-19 reality [here](#)
- The adaptive immune response to COVID-19 [here](#)
- Global pandemic preparedness and response [here](#)
- Postural orthostatic tachycardia syndrome, COVID-19 vaccination & infection [here](#)

Letters and correspondence discussed:

- Coenzyme Q10 therapy in patients with post COVID-19 condition [here](#) and authors' reply [here](#)
- Hybrid immunity and bivalent booster vaccination vs Omicron [here](#) and [here](#)
- Neutralisation of BA.4-5, BA.4.6, BA.2.75.2, BQ.1.1, & XBB.1 with bivalent vaccine [here](#) and [here](#)

Pre-peer review articles featured:

- Long-term respiratory mucosal immune memory to SARS-CoV-2 after infection and COVID-19 vaccination [here](#)
- Effects of intrauterine exposure to SARS-CoV-2 on infants' development [here](#)
- Baby and maternal outcomes after SARS-CoV-2 infection and COVID-19 vaccination during pregnancy [here](#)

Guidance and reports

- The World Health Organization published its weekly epidemiological report on COVID-19 [here](#)
- The CDC published information on SARS-CoV-2 infection prevention and treatment for immunocompromised people in current circulation of Omicron sublineages in the US [here](#)
- The National Clinical Evidence Taskforce COVID-19 released updated recommendations and flowcharts [here](#)
- The Therapeutic Goods Administration (TGA) issued provisional approval to Pfizer's COVID-19 bivalent (COMIRNATY Original/Omicron BA.4-5 COVID-19 vaccine) booster dose vaccine [here](#)

News and blogs

- The US life expectancy in 2021 was at its lowest level since 1996 [here](#)
- Sex-specific effect of COVID-19 on the immune system [here](#)
- Vaccination plus infection offers best protection [here](#)
- What do we know about XBB.1.5 and should we be worried? [here](#)
- The next worrisome coronavirus variant could come from China [here](#)
- Should COVID-19 vaccines be given yearly? [here](#)
- Portable device rapidly detects SARS-CoV-2 antigen [here](#)
- The National Institutes of Health pilots telehealth program for COVID-19 [here](#)
- Patients with mild COVID-19 at risk of some post-COVID-19 condition symptoms [here](#)
- The US Joint Committee Vaccination Immunisation (JCVI) recommends autumn vaccine booster for the most vulnerable [here](#)
- Annual flu-like booster approach may not be appropriate [here](#)

[Click here](#) to subscribe to, or unsubscribe from, the evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), [variants](#) of concern, and [post-acute sequelae of COVID-19 \(long COVID\)](#).



Health

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.